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they identify the most eﬃcient therapy
under study conditions and recommend
this therapy for use. The physician now
has the challenge to translate a therapy
that is eﬃcient under laboratory con-
ditions to a patient who is an individ-
ual person. To accomplish this task, the
physician has to make sure that (i) the
ideal therapy is applicable and eﬀective in
this individual patient taking the special
features into consideration, that (ii) ther-
apy is compliant with the norm including
guidelines, laws and ethical requirements
(conformity) and that (iii) the therapy
meets the patient’s emotional and psy-
chological needs. Together with the pa-
tient, the physician has to ﬁnd the best
way for an individualized optimal ther-
apy. With I-SWOT we introduce an in-
strument which enables us to develop
individualizedmedical therapies for indi-
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vidualpatientsattheGermanAorticCen-
ter Hamburg (DAZH) that are eﬃcient
compliant and needs-oriented (. Table 1;
. Fig. 1).
Table 1 Deﬁnition of some terms of individualizedmedical strategy (IMS)
Eﬃciency The physical success of therapy under controlled study conditions
Eﬀective-
ness
The physical success of therapy for an individual patient under real world condi-
tions
Conformity The compliance of a therapy according to guidelines, laws and ethical issues
Needs
orientation




Individual therapy success in three dimensions, eﬀectiveness, conformity and
needs orientation aimed at goal optimization, becausemaximum success in all
three dimensions simultaneously is hardly possible
Strengths
(S)a
The characteristics of a therapeutic option for maximizing the success of treatment




The characteristics of a therapeutic option that are contrary tomaximizing the
success of treatment in a (i) physical (ii) normative and (iii) emotional dimension
Opportu-
nities (O)a
The characteristics of an individual patient, which are promotive for maximizing
the success of therapy in a (i) physical (ii) normative and (iii) emotional dimension
Threats (T)a The characteristics of an individual patient, which are obstructive for maximizing
the success of therapy in a (i) physical (ii) normative and (iii) emotional dimension
aThese points are evaluated by the physician
What does individual therapy
success mean?
The statement “we do therapy accord-
ing to guidelines” may stand for two
fundamentally diﬀerent ideas of ther-
apy (. Fig. 1). First, this statement may
express the idea of therapy as a one
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Fig. 18 Two forms of guideline-based therapy. Firstly, the evidence-basedmedicine uniform ther-
apy is used to treat every patient according to the samemedical standard and risks technical and eth-
ical treatment failure [1]. Secondly, an individualizedmedical strategy attempts to achieve optimum
adaptation ofmedical standards to individual patients using instruments such as I-SWOT.Measured
as the area of both triangles, therapy success in the three dimensions eﬀectiveness, norm compli-
ance andneeds-oriented is greater in the individualizedmedical therapy (redtriangle) than in the evi-
dence-basedmedicine uniform approach (bluetriangle)
size ﬁts all way of doing standardized
medicine irrespective of individuality;
however, therapy that ignores the phys-
ical conditions of the individual patient
risks technical treatment failure. For
example, an aortic stent graft may be
the best therapeutic option according
to the guidelines but such therapy may
not be feasible because of a speciﬁc
aortic anatomy in an individual patient.
Moreover, standard therapy may ignore
patient’s autonomic will and values and
it may thereby result in ethical failure.
Finally, therapy according to uniform
standards may lack the patient’s mo-
tivational support and therefore result
in emotional failure of therapy. Alter-
natively, we interpret “doing therapy
according to guidelines” as the task to
ﬁt standard recommendations to the
speciﬁc conditions of individual pa-
tients to maximize therapeutic success.
Maximizing therapeutic success requires
maximizing success in three dimensions
comprising (i) biology of the disease and
patient’s physical make-up, (ii) norms
with conformity of therapy with patient’s
autonomy, with medical guidelines, and
laws, and (iii) emotions including the pa-
tient’s motivational support of therapy.
Therefore, individualized therapeutic
success results from success in these
three therapeutic dimensions (i) as ef-
fective therapy, by attaining the physical
goals of therapy, such as elimination
of the aneurysm (“do therapy right”),
(ii) as norm-compliant therapy by at-
taining normative objectives, such as
compliance with guidelines, laws and
ethical values (“do the right therapy”)
and (iii) as needs-oriented therapy by
achieving emotional goals, such as the
patient’s full identiﬁcation with ther-
apeutic eﬀorts (“therapy feels good”)
[1].
To maximize therapeutic success, we
need to consider all three dimensions. To
this end the patient asks himself other
questions than the physician does. The
patient may inquire which (I) physical,
(ii) social and (iii) psychological conse-
quences of therapy he would consider as
an opportunity (O) or as a threat (T) for
his (i) psychological, (ii) normative and
(iii) emotional well-being (. Fig. 2). In
contrast the physician usually askswhich
(i) physical, (ii) social and (iii) psycho-
logical characteristics of the patient may
be an opportunity (O) or a threat (T)
for the (i) physical, (ii) normative and
(iii) the emotional success of the therapy
(. Fig. 3).
Why do we advocate an
individually optimized therapy?
Vascularmedicine is predominantly con-
cerned with treating old and very old pa-
tients with serious comorbidities; there-
fore, the question to be answered is how
thesepatients can livewithdignityduring
the last phases of their lives and whether
they will be able to tolerate and accept
drastic consequencesofa treatment. Dig-
nity and intensity of life, independence
and mobility are the key issues, which
are quite essential. Hence, decisionmak-
ing may be very diﬃcult and absolutely
requires individual solutions. Further-
more, for one patient an amputation can
be the relief of unquenchable pain, for
anotherpatient itmaybe thebeginningof
a newmobility with a prosthesis but also
an irreversible step towards dependency
and surrender.
The compliance with patient-related
priorities may even push the compliance
with guideline-based treatments into
the background, as can be concluded
from various examples of all domains
of medicine. For example, a patient
suﬀering from gastric cancer needs a
gastrectomy and a jejunal substitute
stomach to achieve R0 resection accord-
ing to the guidelines; however, the loss
of quality of life by massive weight loss
and signiﬁcant restriction of food intake
may probably be an intolerable result
of this intervention so that the long-
term survival (with low quality of life)
may be pushed into the background.
Or a patient with ulcerative colitis with-
out complications, whose only curative
chance is the guideline-based therapy of
a proctocolectomy; however, this means
the need for a radical change in life
style and probably occupational dis-
ability by expectedly persistent diarrhea
many times a day. All this could be
a strong argument against a prophylactic
intervention which aims exclusively at
protecting thepatient from the formation
of a carcinoma of the colon.
Many examples from vascular medi-
cine can be cited: the data from the
literature show that the natural clini-
cal course of thoracoabdominal aortic
aneurysm (TAAA) has not yet been ex-
tensively researched; therefore, we only
knowgrosslyatwhichdiameter theriskof
rupture is increased and how aneurysms
develop in the natural history of disease
[2]. Generally, a diameter of 5.5 cm is
considered as an indication for invasive
surgery [3]. Since the introduction of
endovascular techniques, the number of
treatments has increased by the factor of
ten, despite the high mortality and risk
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I-SWOT as instrument to individually optimize therapy of thoracoabdominal aortic aneurysms.
Eﬀective, norm-compliant andmeeting the needs
Abstract
Background. Guidelines summarize medical
evidence, they identify the most eﬃcient
therapy under study conditions and
recommend this therapy for use. The physician
now has the challenge to translate a therapy
that is eﬃcient under laboratory conditions
to a patient who is an individual person. To
accomplish this task the physician has to
make sure that (I) the ideal typical therapy
is applicable and eﬀective in this individual
patient taking the special features into
consideration, that (II) therapy is compliant
with the norm including guidelines, laws and
ethical requirements (conformity) and that
(III) the therapymeets the patient’s needs.
Objective. How can physicians together with
the patients translate the medical evidence
into an individually optimized therapy?
Material and methods. At the German
Aortic Center in Hamburg we use I-SWOT as
an instrument to identify such individually
optimized therapy. With I-SWOT, we present
an instrument with which we have developed
an (I) eﬃcient, (II) conform and (III) needs-
oriented therapeutic strategy for individual
patients.
Results. I-SWOT cross-tabulates strengths (S)
and weaknesses (W) related to therapy with
opportunities (O) and threats (T) related to
individual patients. This I-SWOT matrix identi-
ﬁes four fundamental types of strategy, which
comprise “SO” maximizing strengths and
opportunities, “WT” minimizing weaknesses
and threats, “WO” minimizing weaknesses
and maximizing opportunities and “ST”
maximizing strengths and minimizing
threats. We discuss the case of a patient with
asymptomatic thoracoabdominal aneurysm
to show how I-SWOT is used to identify an
individually optimized therapy strategy.
Keywords
Medical decision making · Evidence
based medicine · Thoracoabdominal
aortic aneurysm · Individualized decision ·
Optimization
I-SWOT als Instrument zur individuell optimierten Therapie bei thorakoabdominalem
Aortenaneurysma. Eﬀektiv, konform und bedürfnisorientiert. Englische Version
Zusammenfassung
Hintergrund. Leitlinien fassen medizinische
Evidenz zusammen, identiﬁzieren die unter
Studienbedingungen eﬀektivste Therapie und
empfehlen diese zur Anwendung. Der Arzt
steht vor der Herausforderung, eine unter
Studienbedingungen eﬀektive Therapie auf
individuelle Patienten anzuwenden. Dazu
muss er sicherstellen, dass (I) die idealtypisch
eﬀektive Therapie auch unter Berücksich-
tigung der individuellen Besonderheiten
seines Patienten einsetzbar und wirksam ist
(Eﬃzienz), dass (II) sein Vorgehen konform
geht mit Leitlinien, Gesetzen- und ethischen
Forderungen (Konformität), und dass (III) die
Therapie den Bedürfnissen des Patienten
gerecht wird (Bedürfnisorientierung).
Fragestellung.Wie können Ärzte zusammen
mit ihren Patienten einen Weg zu einer
individuellen optimalen Therapie ﬁnden?
Material und Methoden. Mit I-SWOT
stellen wir ein Instrument vor, mit dessen
Hilfe wir am Deutschen Aortenzentrum
Hamburg eine (I) eﬃziente, (II) konforme und
(III) bedürfnisorientierte Therapiestrategie für
den individuellen Patienten entwickeln.
Ergebnisse. I-SWOT besteht aus einer
Vierfeldertafel, in deren Kopfzeile wir die
Stärken („strengths“) und Schwächen („weak-
nesses“) verschiedener Therapieoptionen
auﬂisten. In der Vorspalte der Tafel listen
wir die Chancen („opportunities“) und
Gefahren („threats“) auf, die ihre Ursachen in
individuellen Charakteristika des Patienten
haben. Es resultiert eine Vierfeldermatrix, die
vier Grundvarianten der Strategie darstellt.
Erstens: „SO“ als Maximierung von Stärken
und Chancen. Zweitens: „WT“ als Minimierung
von Schwächen und Gefahren. Drittens:
„WO“ als Minimierung von Schwächen
und Maximierung von Chancen. Viertens:
„ST“ als Maximierung von Stärken und
Minimierung von Gefahren. Die vier Typen
der Strategie bilden die Grundvarianten einer
individualisiertenmedizinischen Strategie.
Anhand des Fallbeispiels eines Patientenmit
asymptomatischen thorakoabdominalen
Aortenaneurysma illustrieren wir, wie wir




Evidenzbasierte Medizin · Individualisierte
Entscheidung · Thorakoabdominales
Aortenaneurysma · Optimierung
of paraplegia. Should we really oﬀer this
treatment to a 70-year-old patient who
has an asymptomatic thoracoabdominal
aneurysm, 5.5 cm in size, enjoying good
quality of life without limitations, with
knowledge of all the risks? What will it
really mean to these patients to gain 10
years in a wheelchair if a rupture will
perhaps occur after 8 years? We do not
know. Can we really make this decision
without consulting the patient? Accord-
ing to the idea of I-SWOT, the patient’s
opinion is at least of equal value as that
of the physician.
What is the idea of I-SWOT?
Medical standards require translation
into individual characteristics ofpatients.
Currently, there are no instruments that
provide an easy to use but formal and
systematicmethod to perform this trans-
lation. I-SWOT is an instrument that
performs this task. Here, we brieﬂy
outline how we use I-SWOT at the Ger-
man Aortic Center Hamburg (DAZH).
We presented a detailed description of
I-SWOT and its theoretical basis else-
where [4]. SWOT analysis is a classical
instrument for strategic planning. We
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Fig. 29 3× 3 questions to
optimize therapy from the
patient’s point of view
Fig. 39 3× 3 questions to
maximize therapy from the
physician’s point of view
can ﬁnd examples for its successful prac-
tice in the martial arts [5], management
and project planning [6]. SWOT attains
maximum success by the comparison of
own strengths (S) and weaknesses (W)
with environmental opportunities (O)
and threats (T). From this comparison,
the decision maker chooses a strategic
option for further action. You may con-
sider a boxer who compensates his own
“weaknesses”, exploiting his “strengths”,
and who escapes his opponent’s “threats”
exploiting “opportunities” arising from
his opponent to win victory. In a sim-
ilar way, the physician seeks to exploit
“strengths” and “weaknesses” of diﬀer-
ent therapeutic options balancing these
with patient-associated “opportunities”
and “threats” to maximize therapeutic
success.
We show that I-SWOT is a method
which can be used by healthcare pro-
fessionals as a standardized method to
optimize the therapeutic outcome based
on medical guidelines. In this article we
choose the doctor’s perspective,whoper-
forms I-SWOT to achieve an optimum
therapeutic strategy. Alternatively, the
patient will be able to conduct his own
I-SWOT analysis by using information
and knowledge of the therapeutic op-
tions tomaximizehis orherbeneﬁts from
treatment. The optimization of patient’s
therapy could be achieved by matching
both points of view in a doctor–patient
dialogue, which is the major method to
approachanoptimal therapeuticdecision
[1].




which strengths (S) and weaknesses (W)
ofvarious therapeuticoptionsare listed in
the column headings. In the left column
of the table we ﬁll in opportunities (O)
and threats (T) related to the individual
characteristics of the patient. The result is
a matrix that represents the four classical
types of strategies (. Fig. 4):
The SO strategy maximizes both the
therapeutic strengths and patient-related
opportunities (maxi-maxi strategy). This
Gefässchirurgie · Suppl 1 · 2017 S11
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Fig. 48 I-SWOTmatrix for the evaluation of therapy-related strengths andweaknesses in relation to
the patient-related opportunities and threats for the success of treatment
strategy is typically assumed in situations
with abundant availability of both thera-
peutic strengths (S) and patient’s oppor-
tunities (O).The vulnerability of this type
of strategy lies in the overestimation of
the strengths of novel or complex tech-
niques, and overconﬁdence in patient-
related opportunities.
The WT strategy minimizes both
therapeutic weaknesses and patient-re-
lated threats (mini-mini strategy). Such
a strategy might be chosen in precari-
ous situations, when therapeutic options
are sparse and threats are mounting.
Physicians should strive to avoid such
unfortunate situations and seek other
strategic options; however, aWTstrategy
may be useful to gain time to improve
the initial situation, e. g by stabilizing
a patient, to organize advanced therapy
or to transfer the patient to specialized
centers with better therapeutic options.
The WO strategy minimizes weak-
nesses and maximizes opportunities
(mini-maxi or opportunity-oriented
strategy). Physicians prefer to choose
this strategy in situations where ther-
apeutic weaknesses are evident, while
external opportunities are appealing.
A physician could, for example, orga-
nize a transport by helicopter to the
next cardiac surgery medical center for
patients with acute type A aortic dissec-
tion; however, physicians and hospitals
should try to reduce their own ther-
apeutic weaknesses and develop their
strengths.
The ST strategy maximizes own
strengths andminimizes patient’s threats
(maxi-mini or strength-oriented strat-
egy). Physiciansmay choose this strategy
in the face of desperate disease constel-
lations, where maximizing own thera-
peutic strengths may be the only way to
overcome substantial patient’s threats.
Physicians may focus on their own in-
tuition and their surgical and medical
capabilities to rescue patients despite
threatening conditions, especially when
established or well-deﬁned therapeutic
options are not available. The challenge
of a strength-oriented approach is to
always protect oneself against undue
self-reliance.
The four steps of I-SWOT
I-SWOT is a technique which may be
intuitively applied: for example, a high-
performance athlete weighs his abilities
against those of his competitors with-
out using a strategy matrix. Similarly,
clinical decision-making is usually done
without explicit use of the decision-mak-
ing techniques. In our case conferences
at the DAZH we usually apply I-SWOT
without applying formalized step by step
techniques. The following illustrationex-
plains the procedure in four steps:
1. Deﬁne the goal of therapy and the
spectrum of evidence-based therapeu-
tic options. In this step we analyze the
clinical problem of a patient with aortic
disease to identify the therapeutic goal.
Examples of such goals are protection
against aortic rupture, prevention of false
lumen expansion in chronic aortic dis-
section type Stanford B, or stabilization
of contained rupture of an abdominal
aortic aneurysm. First, we describe the
spectrum of evidence-based therapeutic
options for a given therapeutic goal. Let
us consider a patient with asymptomatic
TAAA where we identify protection
against aortic rupture as therapeutic
goal. Next, we identify evidence-based
consensus recommendations for ﬁve
distinct therapeutic options as follows
[7–10]: conservative therapy (A) imply-
ingmedicinal therapywith angiotensin II
receptor blockers (ARB), angiotensin-
converting enzyme inhibitors (ACEI),
beta adrenergic blockers (BAB) or cal-
cium channel blockers (CCB), therapy
for obstructive sleep apnea syndrome
(OSAS), and behavioral modiﬁcation
with avoidance of Valsalva maneuvers
or isometric muscle activities. Another
option is endovascular therapy using so-
called chimney, snorkel, periscope, or
sandwich techniques (B) [7]. Complete
endovascular repair with fenestrated and
branched endovascular stent grafts (C)
is another therapeutic option. Alterna-
tively, hybrid procedures with visceral
vessel debranching and stent grafts for
the aorta (D), or open surgical repair
with complete prosthetic graft replace-
ment of TAAA (E) may be used to treat
TAAA (. Table 2; [11]).
2. Identify the strengths and weak-
nesses of each therapeutic option (SW
matrix). This step requires systematic
assessment of the strengths and weak-
nesses of each therapeutic option. To
this end, we integrate information from
clinical studies, case reports, guidelines,
and from our own experiences. We list
this evidence in a matrix, representing
the strengths and weaknesses proﬁle
of all therapeutic options for each de-
ﬁned treatment goal. . Table 2 shows
the SW matrix for all ﬁve therapeutic
options (A–E), identiﬁed as useful to
attain the goal of protecting patients
with asymptomatic TAAA from rupture.
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Table 2 Protection against rupture by asymptomatic TAAA: strengths-weaknessesmatrix for elective therapeutic options
Therapeutic options Strengths (S) Weakness (W)
(A) Conservative
therapy
No restrictions for quality of life (S1)
Outpatient treatment (S2)






Prosthetic exclusion of TAAA (S3)
No thoracotomy (S4)
No laparotomy (S5)
Option for patients with high risk for open surgi-
cal repair (S6)
Immediate availability of prosthesis (S7)
Good 30-day survival and immediate outcome
(S8)
Short stay in the ICU, hospital and rehabilitation
(S9)
Risk of endoleaks, progression of aneurysm (W3)
Bypass or transposition of the left subclavian artery may be needed
(W4)
Unsuitable vascular anatomy (W5)
Endoprosthesis-related risks (W6)
Procedural risks of endoprosthesis (W7)
Risk of organ ischemia (W8)
Oﬀ-label therapy (W9)
Result depends on the surgeon (W10)
Long-term results unknown (W11)
Frequent check-ups with CT imaging (W12)







Prosthetic exclusion of TAAA (S3)
No thoracotomy (S4)
No laparotomy (S5)
Option for patients with high risk for open surgi-
cal repair (S6)
Good 30-day survival and immediate outcome
(S8)
Short stay in the ICU, hospital and rehabilitation
(S9)
Good results at the DAZH (S10)
Risk of endoleaks, progression of aneurysm (W3)
Bypass or transposition of the left subclavian artery may be needed
(W4)
Unsuitable vascular anatomy (W5)
Endoprosthesis-related risks (W6)
Procedural risks of endoprosthesis (W7)
Result depends on the surgeon (W10)
Long-term results unknown (W11)
Frequent check-ups with CT imaging (W12)







Prosthetic exclusion of TAAA (S3)
No thoracotomy (S4)
Option for patients with high risk for open surgi-
cal repair (S6)
Immediate availability of the prosthesis (S7)
Practicable despite unfavorable landing zones
(S11)
Risk of endoleaks, progression of aneurysm (W3)
Bypass or transposition of the left subclavian artery may be needed
(W4)
Endoprosthesis-related risks (W6)
Procedural risks of endoprosthesis (W7)
Procedural risks of laparotomy (W8)
Result depends on the surgeon (W10)
Long-term results unknown (W11)
Frequent check-ups with CT imaging (W12)
Laparotomy essential (W15)
Aortic rupture in the interval before reoperation (W16)
Longer ICU stay, hospital stay and rehabilitation (W17)
(E) Open TAAA
operation
Complete resection of TAAA (S12)
Reimplantation of segmental arteries possible
(S13)
Operation applicable for all aortic pathologies
(S14)
Good results at the DAZH (S10)
First choice therapy for Marfan syndrome (15)
Long-term results >20 years (S16)
Results depend on the surgeon (W10)
Longer ICU stay, hospital stay and rehabilitation (W17)
Pseudo- or patch aneurysm, prosthetic infection (W18)
Thoracotomy and laparotomy (W19)
Not possible in high-risk cases for open surgery (W20)
Specialized anesthesia, neuro-monitoring (W21)
CIN contrast-induced nephropathy, DAZH German Aortic Center of Hamburg, ICU intensive care unit, TAAA thoracoabdominal aortic aneurysm,
TAAA I, II, III, IV, and V refer to the Crawford classification of TAAA
Explanatory notes: W4 Bypass or left subclavian artery transposition according to the guidelines [13];W5 Hostile aortic landing zone (landing zone <2 cm,
massive aortic calcification or thrombosis, “gothic aortic arch” anatomy), unsuitable aortic anatomy (aortic kinking, narrow vessel caliber, unfavourable
aortic anatomy of outflow vessels), unsuitable access to vessels (calcification, kinking, simultaneous access from multiple vessels);W6 Stent migration, stent
collapse (risk factors are small diameter of aortic landing zone, aggressive oversizing, narrow aortic curvature with “bird-beaking” configuration);W7 High
radiation exposure, high contrast load with increased risk of allergic reactions, complications due to complex arterial access techniques, contrast-induced
nephropathy (CIN) and dialysis with subsequent risk factors for CIN: diabetesmellitus, age > 75 years periprocedural volume depletion, heart failure, cirrhosis
or nephrosis, arterial hypertension, proteinuria, pretreatment with nonsteroidal anti-inflammatory drugs (NSAIDs), initial intra-arterial injection of contrast
medium [7];W8 Risk of organ ischemia (stroke, paraparesis, paraplegia especially with endograft >15 cm in length), visceral ischemia, renal artery infarctions;
W19 Thoracotomy with aortic clamping, extracorporeal circulation, and unilateral pulmonary ventilation; W20 Patients who generally fulfil at least three
of the following criteria: chronic arterial hypertension, chronic obstructive pulmonary disease with FEV1 < 1.0, coronary heart disease with myocardial
infarction, stenting or aortocoronary bypass, heart failure with LVEF < 35% and >NYHA I, chronic renal failure with creatinine 1.2 mg/dl, American Society of
Anesthesiologists score (ASA) ≥ 3, pre-existing aortic operation with thoracotomy or infrarenal aortic prosthetic grafts [14]
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Fig. 58 Example of a standardDAHZ template for I-SWOT for identiﬁcation of an optimal individual therapeutic strategy for
a TAAA
3. Assess individual patient character-
istics as opportunities and threats for
therapy (OT matrix). The core of an
individualized treatment strategy is the
adjustment of medical standards to the
characteristics of individual patients
[12]; therefore, in this third step of the
I-SWOT analysis, we register critical
individual qualities of the individual
patient, representing an opportunity or
a threat to the therapy. We principally
acquire these individual qualities in
three relevant dimensions: (i) physical
features, e. g. characteristics of aor-
tic pathology, comorbidities, previous
medication, allergies, and psychological
resilience factors; (ii) social character-
istics, such as family, housing, ﬁnancial
resources and other socioeconomic re-
silience factors; (iii) psychological and
intellectual factors, such as the compe-
tence to understand and to cooperate,
the status of education, mental disorders,
such as schizophrenia or depression, at-
titudes towards life, such as optimism
or pessimism, motivation, risk aﬃnity,
and psychological and mental resilience
factors. Finally, we record the individual
values and preferences with potential
impact on the therapeutic goal attain-
ment. Finally, we appraise the individual
factors of our patients as opportunities
or threats according to the treatment
goals and list them in an OT matrix.
4. Establish a 4-ﬁeld I-SWOT matrix
to identify an individualized medical
strategy. In this ﬁnal step of I-SWOT
we set up an individualized therapeutic
strategy for the patient. To facilitate the
strategizing process, we employ I-SWOT
tables which we prefabricate for some
of standard therapy goals. In . Fig. 5 we
show the example of such a fabricated
I-SWOT for the therapeutic goal of pro-
tection against TAAA rupture (. Fig. 5).
In the top row of this I-SWOT matrix
form we list the summary of all possible
strengths and weaknesses for the ﬁve
treatment options (refer to step 2 and
. Table 1). Unlike the top rows, the ﬁrst
column in I-SWOT matrix table is not
ﬁlled out: here, we document the in-
dividual characteristics of every patient
as opportunities or threats for achieving
the therapeutic goal. From the cross-
tabulation of standardized therapeu-
tic strengths and weaknesses with the
patient’s individual opportunities and
threats we are able to set up an individ-
ualized medical strategy that maximizes
therapeutic success for the individual
patient.
Example for the application
of I-SWOT
We present the example of a well-
groomed 70-year-old man, who was
working as a general practitioner up to
5 years ago in his own practice. He is
still interested in medical aﬀairs and he
is highly reliable and adheres to therapy
(O1). His current annual check com-
puted tomography angiography (CTA)
shows progression of aortic diameter of
a TAAA from 5.7 cm in the last year (T1)
to 6.4 cm on the current CT scan (T2).
The patient has no symptoms. Multidis-
ciplinary review of the CTA images in
our aortic conference showed that the
visceral vessels could only be supplied at
great expense by a completely endovas-
cular procedure (T3). Comorbidities are
comprised of untreated arterial hyper-
tension (HTN), a myocardial infarction
with a triple aortocoronary bypass (ACB)
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4 years ago, and chronic obstructive pul-
monary disease (COPD) with FEV1 <
1.0 (T4). He appears to be physically
resilient (O2), lives together with his
wife and he takes vacation trips to other
cities almost three times a year.
In step 1 of the I-SWOT analysis we
identify the goal of the therapy as pro-
tection from rupture in asymptomatic
TAAA.We have ﬁve diﬀerent and techni-
cally possible options to achieve this goal
which we principally deemed applicable
in our patient. In step 2 we sketch out
a strengths-weakness matrix of the ﬁve
treatment options (. Table 1) and ﬁll the
strengths-weaknesses proﬁle in the top
line of our therapy standard for asymp-
tomatic TAAA (. Fig. 5). In step 3 we
categorize the individual characteristics
of the patient as opportunities (O1–2)
and threats (T1–4) for the treatment of
TAAA. Finally, we list these opportuni-
ties and threats in the I-SWOT form as
O1 and O2 and as T1, T2, T3 and T4,
respectively. In the ﬁnal step we discuss
the various therapeutic strategies among
colleagues and then together with the
patient to integrate the patient’s personal
preferences, values and attitudes along
with the other opportunities and threats
into an individualized strategy. In the
following we apply the I-SWOT matrix
to present four possible individualized
strategies for the patient:
SOstrategy (maxi-maxi).Acompleteen-
dovascular repair of TAAA with a fenes-
trated endovascular stent graft (optionC)
requires an experienced surgeon in con-
sideration of the delicate visceral vascu-
lar anatomy and it takes a patient with
the ability and disposition to measure up
and assess risks of an innovative therapy
realistically and face these risks for the
purpose ofmaximumachievablemedical
beneﬁts. The decision for a completely
endovascular repair maximizes the pa-
tient’s opportunities O1–2 and the ther-
apeutic beneﬁts S3–6 and S8–10.
WT strategy (mini-mini). An exclusively
conservative therapy (optionA) canmin-
imize therapeutic weaknesses W3–11,
W13–14, W16–20 by reducing thera-
peutic measures to a minimum. Simul-
taneously, this strategy minimizes the
patient’s existing threats of the T3–4 for
a more aggressive therapeutic approach;
however, it is diﬃcult to imagine that
our patient will agree with this kind of
strategy. Nevertheless, his personal sit-
uation may cause at least his temporary
commitment, for example, because he
needs some time to get over the sudden
andunexpected loss of hiswife to recover
from this stroke of fate.
WO strategy (mini-maxi). We may sug-
gest a hybrid procedures with visceral
vessel debranching and aortic stent graft
(option D). By performing a visceral de-
branching, we may minimize the thera-
peutic weaknessesW1–3, W8, W14, and
W16–19 of alternative therapeutic op-
tions but this method requires an open
surgical and an endovascular approach,
which is usually done as a 2-stage pro-
cedure; therefore, this method requires
discipline, capacity for discernment and
compliance of the patient which means
that we have to rely heavily on the pa-
tient’s opportunities O1–2.
ST strategy (maxi-mini).An open surgi-
cal repair with complete prosthetic graft
replacement of TAAA (option E) maxi-
mizes therapeutic strengths S12–14 and
S16 because it ensures a complete resec-
tion of the aneurysm by complete re-
section of TAAA and replacing the af-
fected aorta with re-implantation of all
relevant aortic side branches. This strat-
egy minimizes the patient’s threats T1–3
of extended aortic disease; however, this
option requires a patientwho iswilling to
accept the strains and risks of maximum
surgery, in order to have the chance to
keep the life-threatening disease under
control for the rest of his life. It also ne-
cessitates a surgeon and a team with the
ability and experience to perform such
extensive surgery quickly and safely.
Conclusion
I-SWOT is a method that matches ideal
medical standards and guideline recom-
mendations with individual characteris-
tics of a patient. In this way it becomes
possible tomaximize therapeutic success
for the individual patient. I-SWOT illus-
trates that there is a choice of four funda-
mental types of strategy and that the per-
sonal dispositionof the physician and the
patient, expressed as their strengths and
weaknesses and as the external threats
and opportunities, is important for the
choice of strategy. We think that prospec-
tive guidelines and evidence-based rec-
ommendations should provide strength-
weaknessmatrices for alternative therapy
options. I-SWOTanalysis isaﬂexible tool
concerning its grade of formalization so
that time exposure can be easily adjusted
according to the situation. The appli-
cation of standardized templates keeps
time requirements adequate even if the
grade of formalization is high. In our
experience, I-SWOT is an easy to use in-
strument that helps to prevent technical,
ethical and psychological treatment fail-
ures. In comparison to a standardized
one ﬁts for all application of the medical
guidelines, I-SWOTmaximizes the indi-
vidual therapeutic success by optimizing
all three dimensions of treatment goals:
eﬀectiveness, compliance, and needs ori-
entation.
Conclusion for practice
There are two diﬀerent ways of how
to perform guideline-based therapy.
One way is the one size ﬁts all approach
where all patients receive identical ther-
apy according to guideline standards;
however, this way of therapy risks tech-
nical, ethical and psychological failure.
Therefore, the alternative way of per-
forming guideline-based therapy is
to establish an individualized medical
strategy. Such individualized medical
strategies aim tomaximize therapeu-
tic success in the technical, ethical and
psychological dimension. Thereby this
type of therapy translates guideline rec-
ommendations into an eﬀective, norm-
compliant, andmeeting the patient’s
needs type of therapy. I-SWOT is an easy
to use instrument that supports medical
decision makers to identify an individ-
ualizedmedical strategy to maximize
therapeutic success.
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